Osaka, Japan

Takayuki Fujito

USPTO Granted Patents = 1 

 

Average Co-Inventor Count = 8.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Takayuki Fujito: Innovator in Pharmaceutical Compounds

Introduction

Takayuki Fujito is a notable inventor based in Osaka, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that interact with specific receptors in the body. His work is characterized by a focus on innovative drug substances that have the potential to improve therapeutic outcomes.

Latest Patents

Fujito holds a patent for a compound known as "Salt and crystal form of compound having agonistic activity to S1P5 receptor." This compound, referred to as Compound I, exhibits high S1P receptor-selective agonist activity. The patent also covers the crystal forms of Compound I, the salts of Compound I, and the crystal forms of these salts, which are provided as drug substances for pharmaceuticals. He has 1 patent to his name, showcasing his expertise in this specialized area.

Career Highlights

Takayuki Fujito is associated with Ono Pharmaceutical Co., Ltd., a company known for its commitment to research and development in the pharmaceutical industry. His role at Ono Pharmaceutical has allowed him to contribute to groundbreaking research and the development of innovative drug therapies.

Collaborations

Fujito has collaborated with notable colleagues, including Shuhei Otani and Naoko Imura. These collaborations have likely enhanced the research and development process, leading to advancements in pharmaceutical compounds.

Conclusion

Takayuki Fujito's work in the pharmaceutical field exemplifies the impact of innovative thinking on drug development. His contributions, particularly in the area of S1P receptor-selective compounds, highlight the importance of research in creating effective therapeutic solutions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…